BioCentury
ARTICLE | Clinical News

New NASH readouts for NGM, Bristol

April 5, 2017 10:41 PM UTC

New data showed that fibroblast growth factor (FGF) analogs from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) each reduced liver fat in separate Phase II studies to treat non-alcoholic steatohepatitis. The data appeared in abstracts released ahead of the European Association for the Study of the Liver meeting, slated for April 19-23 in Amsterdam.

Each of two tested doses of NGM282, NGM's engineered form of FGF19, significantly reduced absolute liver fat content vs. placebo after 12 weeks. A 6 mg dose led to an 11.9% reduction and a 3 mg dose led to a 9.7% reduction, vs. 0.9% for placebo (p<0.001 for both). The primary endpoint was achieving a liver fat reduction of at least 5%...